Literature DB >> 28090312

RANKL signaling to the liver associated with type 2 diabetes risk.

.   

Abstract

Entities:  

Year:  2013        PMID: 28090312      PMCID: PMC5185355          DOI: 10.1038/bonekey.2013.99

Source DB:  PubMed          Journal:  Bonekey Rep        ISSN: 2047-6396


× No keyword cloud information.
  1 in total

1.  Blockade of receptor activator of nuclear factor-κB (RANKL) signaling improves hepatic insulin resistance and prevents development of diabetes mellitus.

Authors:  Stefan Kiechl; Jürgen Wittmann; Andrea Giaccari; Michael Knoflach; Peter Willeit; Aline Bozec; Alexander R Moschen; Giovanna Muscogiuri; Gian Pio Sorice; Trayana Kireva; Monika Summerer; Stefan Wirtz; Julia Luther; Dirk Mielenz; Ulrike Billmeier; Georg Egger; Agnes Mayr; Friedrich Oberhollenzer; Florian Kronenberg; Michael Orthofer; Josef M Penninger; James B Meigs; Enzo Bonora; Herbert Tilg; Johann Willeit; Georg Schett
Journal:  Nat Med       Date:  2013-02-10       Impact factor: 53.440

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.